Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.60 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568741 | 0.96 | IMPDH2 (0.63) | IMPDH2ROCK2ROCK1PRMT3NOTUM | |
| SCHEMBL30209208 | 0.88 | IMPDH2 (0.54) | IMPDH2ROCK2ROCK1PRMT3NOTUM | |
| SCHEMBL30209215 | 0.88 | IMPDH2 (0.54) | IMPDH2ROCK2ROCK1PRMT3NOTUM | |
| SCHEMBL14124392 | 0.86 | ROCK2 (0.61) | IMPDH2ROCK2PRMT3NOTUMALDH1A1 | |
| SCHEMBL6630095 | 0.86 | IMPDH2 (0.64) | IMPDH2ROCK2ROCK1PRMT3ALDH1A1 | |
| SCHEMBL20353458 | 0.86 | NOTUM (0.71) | IMPDH2ROCK2ROCK1PRMT3NOTUM | |
| SCHEMBL20353459 | 0.86 | ROCK2 (0.57) | IMPDH2ROCK2ROCK1PRMT3NOTUM | |
| SCHEMBL24969695 | 0.84 | ALDH1A1 (0.63) | KDM4EALDH1A1MAPT | |
| SCHEMBL30206829 | 0.84 | ALDH1A1 (0.63) | KDM4EALDH1A1MAPT | |
| SCHEMBL12058848 | 0.82 | POLB (0.65) | IMPDH2ROCK2ROCK1PRMT3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257192-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257192-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2023-10-11 | — | — | EP | disclosed |
| EP-3505513-B1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | IND TECH RES INST (TW) | 2023-09-27 | — | — | EP | disclosed |
| EP-3505513-B1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | IND TECH RES INST (TW) | 2023-09-27 | — | — | EP | disclosed |
| CN-109956900-B | Compounds and pharmaceutical compositions comprising the same | 财团法人工业技术研究院 | 2023-02-03 | — | — | CN | disclosed |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-30 | — | — | US | disclosed |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-30 | — | — | US | disclosed |
| CN-107108593-B | Substituted oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II | 美迪福伦DBT有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3505513-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2019-07-03 | — | — | EP | disclosed |
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-06-27 | — | — | US | disclosed |
| EP-3224252-B1 | SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II | MEDIFRON DBT INC (KR) | 2019-01-09 | — | — | EP | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9771359-B1 | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II | MEDIFRON DBT INC. (KR) | 2017-09-26 | — | — | US | disclosed |
| US-20170253586-A1 | Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II | MEDIFRON DBT INC. (KR) | 2017-09-07 | — | — | US | disclosed |
| EP-2307387-B1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8071586-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2307387-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRK4, NCOA4, GRK3 | IMPDH2 3237/4885ROCK2 1808/4885ROCK1 2416/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | GRK4, NCOA4, GRK3 | IMPDH2 3237/4885ROCK2 1808/4885ROCK1 2416/4885 |
| US-20170253586-A1 | Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II | TRPV1, TRPV2, GPR17 | IMPDH2 2666/4885ROCK2 4662/4885ROCK1 4851/4885 |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | IMPDH2 4323/4885ROCK2 1735/4885ROCK1 1147/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.